German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T Biosciences to advance next-generation T-cell-based immuno-oncology therapies. BI will contribute its proprietary patient-derived T-cell receptor (TCR) data to help identify binding antigens using 3T’s discovery platform. Under the terms, BI will provide an undisclosed upfront payment and cover research and development expenses, with both companies positioned to earn royalties from future sales.
This marks the second collaboration between Boehringer and 3T following a successful 2023 partnership. According to the companies, the cumulative value for 3T from both agreements could reach up to USD 538.5 million.- Flcube.com
